Dynacirc Cr

Hypertensive disease

Treatment

1 FDA approval

20 Active Studies for Dynacirc Cr

Treatment for

Hypertensive disease

What is Dynacirc Cr

IsradipineThe Generic name of this drug

Treatment SummaryIsradipine is a type of drug called a calcium channel blocker (CCB). It works by blocking the movement of calcium into cells in the heart and arteries, lowering blood pressure. Isradipine is the most powerful CCB in its class and is used to treat mild to moderate high blood pressure. It binds to calcium channels with high precision and is more selective for arterial smooth muscle cells than other CCBs.

DynaCircis the brand name

image of different drug pills on a surface

Dynacirc Cr Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

DynaCirc

Isradipine

1998

Approved as Treatment by the FDA

Isradipine, also known as DynaCirc, is approved by the FDA for 1 uses including Hypertensive disease .

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Effectiveness

How Dynacirc Cr Affects PatientsIsradipine helps lower blood pressure by blocking calcium from entering cells. Normally, calcium enters cells and binds to calmodulin, which then starts a process that causes the cells to contract. By preventing calcium from entering the cells, isradipine stops the contraction process and causes the vessels to relax, leading to an overall decrease in blood pressure.

How Dynacirc Cr works in the bodyIsradipine belongs to a class of drugs called calcium channel blockers, which are used to treat high blood pressure. It specifically targets L-type calcium channels, which are present in muscle cells and help to control contraction. Isradipine works by binding to inactive calcium channels and keeping them from activating, which can reduce the contraction of artery walls. It has extra effects on arteries compared to other calcium channel blockers, and is unlikely to affect the heart or the conduction system at therapeutic doses.

When to interrupt dosage

The endorsed dose of Dynacirc Cr is contingent upon the indicated condition. The quantity of dosage is subject to the method of delivery set forth in the below table.

Condition

Dosage

Administration

Hypertensive disease

, 2.5 mg, 5.0 mg, 10.0 mg

, Oral, Capsule, Capsule - Oral, Tablet - Oral, Tablet, Tablet, extended release - Oral, Tablet, extended release, Tablet, film coated, extended release - Oral, Tablet, film coated, extended release

Warnings

There are 20 known major drug interactions with Dynacirc Cr.

Common Dynacirc Cr Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be decreased when combined with Isradipine.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be decreased when combined with Isradipine.

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Isradipine.

Alpelisib

Major

The metabolism of Alpelisib can be decreased when combined with Isradipine.

Amifostine

Major

Isradipine may increase the hypotensive activities of Amifostine.

Dynacirc Cr Toxicity & Overdose RiskOverdosing on isradipine can cause tiredness, an abnormally fast heartbeat, and low blood pressure. Mice and rabbits have been found to be more sensitive to the overdose, with doses of over 200mg/kg and 50mg/kg, respectively, resulting in death. Rats, however, were able to tolerate doses of up to 2000mg/kg without any negative effects on survival.

image of a doctor in a lab doing drug, clinical research

Dynacirc Cr Novel Uses: Which Conditions Have a Clinical Trial Featuring Dynacirc Cr?

18 active trials are in progress to evaluate the potential of Dynacirc Cr in providing relief for Hypertensive disease.

Condition

Clinical Trials

Trial Phases

Hypertensive disease

23 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3